Literature DB >> 12379625

Preliminary guidelines for diagnosing and treating tuberculosis in patients with rheumatoid arthritis in immunosuppressive trials or being treated with biological agents.

D E Furst1, J Cush, S Kaufmann, J Siegel, R Kurth.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12379625      PMCID： PMC1766699          DOI： 10.1136/ard.61.suppl_2.ii62

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  1 in total

Review 1.  How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults?

Authors:  G W Comstock
Journal:  Int J Tuberc Lung Dis       Date:  1999-10       Impact factor: 2.373
  1 in total
  20 in total

Review 1.  Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other immune mediated inflammatory diseases (May 2003).

Authors:  D E Furst; F C Breedveld; J R Kalden; J S Smolen; G R Burmester; M Dougados; P Emery; A Gibofsky; A F Kavanaugh; E C Keystone; L Klareskog; A S Russell; L B A van de Putte; M H Weisman; A F Kavenaugh
Journal:  Ann Rheum Dis       Date:  2003-11       Impact factor: 19.103

2.  ELISPOT-IFN-gamma assay instead of tuberculin skin test for detecting latent Mycobacterium tuberculosis infection in rheumatic patients candidate to anti-TNF-alpha treatment.

Authors:  Stefania Girlanda; Paola Mantegani; Elena Baldissera; Patrizia Aiello; Manuela Ratti; Maria Grazia Sabbadini; Claudio Fortis
Journal:  Clin Rheumatol       Date:  2010-07-20       Impact factor: 2.980

3.  Pulmonary involvement in ankylosing spondylitis.

Authors:  Percival D Sampaio-Barros; Elza Maria F P Cerqueira; Sílvio M Rezende; Lucimara Maeda; Roseneide A Conde; Verônica A Zanardi; Manoel Barros Bértolo; José Ribeiro de Menezes Neto; Adil M Samara
Journal:  Clin Rheumatol       Date:  2006-03-30       Impact factor: 2.980

Review 4.  Immunosuppression related to collagen-vascular disease or its treatment.

Authors:  Carol Dukes Hamilton
Journal:  Proc Am Thorac Soc       Date:  2005

Review 5.  Clinical observations programme in SpA: disease parameters, treatment options and practical management issues.

Authors:  Dirk Elewaut; Filip Van den Bosch; Gust Verbruggen; Filip de Keyser; Bert Vander Cruyssen; Herman Mielants
Journal:  Rheumatol Int       Date:  2008-09-26       Impact factor: 2.631

6.  Follow-up results of isoniazid chemoprophylaxis during biological therapy in Colombia.

Authors:  Juan Carlos Cataño; Milena Morales
Journal:  Rheumatol Int       Date:  2015-03-13       Impact factor: 2.631

7.  [Recommendations for tuberculosis screening before initiation of TNF-alpha-inhibitor treatment in rheumatic diseases].

Authors:  R Diel; B Hauer; R Loddenkemper; B Manger; K Krüger
Journal:  Z Rheumatol       Date:  2009-07       Impact factor: 1.372

8.  Comparison of in vitro-specific blood tests with tuberculin skin test for diagnosis of latent tuberculosis before anti-TNF therapy.

Authors:  Jérémie Sellam; Haifa Hamdi; Carine Roy; Gabriel Baron; Marc Lemann; Xavier Puéchal; Maxime Breban; Francis Berenbaum; Marc Humbert; Karin Weldingh; Dominique Salmon; Philippe Ravaud; Dominique Emilie; Xavier Mariette
Journal:  Ann Rheum Dis       Date:  2007-04-24       Impact factor: 19.103

9.  A case of tuberculous arthritis following the use of etanercept.

Authors:  Seung Won Choi; Jong Joon Ahn; Young Tae Hwang; Sang Hoon Koh; Sung Do Cho
Journal:  Korean J Intern Med       Date:  2009-11-27       Impact factor: 2.884

10.  Biological therapies for the treatment of juvenile idiopathic arthritis: Lessons from the adult and pediatric experiences.

Authors:  Matthew L Stoll; Alisa C Gotte
Journal:  Biologics       Date:  2008-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.